Abstract
Summary
KEY FINDINGS
The Europe cough syrup market is evaluated to project a CAGR of 2.79% over the forecasted years of 2021 to 2028. The market growth of the region is facilitated by chief factors such as the increasing burden of respiratory diseases as well as the rising geriatric populace.
MARKET INSIGHTS
The Europe cough syrup market growth evaluation constitutes the assessment of Poland, the United Kingdom, Italy, Germany, France, Russia, Belgium, and the rest of Europe. Chronic obstructive pulmonary disease (COPD) and chronic bronchitis are increasingly prevalent across the French adult population. As per industry sources, air pollution is responsible for approximately 48,000 premature deaths in the country annually. Moreover, air pollution increases the risk of developing COPD, lung cancer, emphysema, and bronchitis. Lung cancer is also the second-highest leading cause of mortality in France.
On the other hand, lung cancer is the third leading cause of death in Italy. Lung cancer deaths in the country reached 6.34% or 34,188 of the total fatalities in 2018, according to the World Health Organization (WHO). Furthermore, Chronic Respiratory Diseases (CRDs) are commonly observed across Italy’s adult population. Around 1 in 4 people within the age bracket of 65–84 years are diagnosed with COPD or asthma in the country. Besides, COPD, including chronic bronchitis as well as emphysema, significantly contributes to chronic lower respiratory diseases (CLRD) mortality in Italy. Hence, these factors are expected to propel market growth in Europe during the estimated period.
COMPETITIVE INSIGHTS
Some of the key companies operating in the market are Sanofi SA, Novartis International AG, Reckitt Benckiser Group PLC, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
Table of Contents
1 RESEARCH SCOPE & METHODOLOGY
1.1 STUDY OBJECTIVES
1.2 SCOPE OF STUDY
1.3 METHODOLOGY
1.4 ASSUMPTIONS & LIMITATIONS
2 EXECUTIVE SUMMARY
2.1 MARKET SIZE & ESTIMATES
2.2 MARKET OVERVIEW
3 MARKET DYNAMICS
3.1 KEY DRIVERS
3.1.1 RISING GERIATRIC POPULATION
3.1.2 INCREASE IN CHRONIC RESPIRATORY DISEASES
3.2 KEY RESTRAINTS
3.2.1 OVERDOSE RISKS ASSOCIATED WITH COUGH SYRUP
3.2.2 GOVERNMENT REGULATIONS AND RESTRICTIONS
4 KEY ANALYTICS
4.1 IMPACT OF COVID-19 ON COUGH SYRUP MARKET
4.2 KEY MARKET TRENDS
4.3 PORTER’S FIVE FORCES ANALYSIS
4.3.1 BUYERS POWER
4.3.2 SUPPLIERS POWER
4.3.3 SUBSTITUTION
4.3.4 NEW ENTRANTS
4.3.5 INDUSTRY RIVALRY
4.4 OPPORTUNITY MATRIX
4.5 VENDOR LANDSCAPE
5 MARKET BY PRODUCT TYPE
5.1 COUGH SUPPRESSANTS/ANTITUSSIVES
5.2 COMBINATION MEDICATIONS
5.3 EXPECTORANTS
6 MARKET BY AGE GROUP
6.1 ADULT
6.2 PEDIATRIC
7 MARKET BY DISTRIBUTION CHANNELS
7.1 RETAIL PHARMACY
7.2 HOSPITAL PHARMACY
7.3 ONLINE PHARMACY
8 GEOGRAPHICAL ANALYSIS
8.1 EUROPE
8.1.1 MARKET SIZE & ESTIMATES
8.1.2 KEY DRIVERS
8.1.3 KEY CHALLENGES
8.1.4 KEY PLAYERS
8.1.5 COUNTRY ANALYSIS
- 8.1.5.1 UNITED KINGDOM
- 8.1.5.2 GERMANY
- 8.1.5.3 FRANCE
- 8.1.5.4 ITALY
- 8.1.5.5 RUSSIA
- 8.1.5.6 BELGIUM
- 8.1.5.7 POLAND
- 8.1.5.8 REST OF EUROPE
9 COMPETITIVE LANDSCAPE
9.1 KEY STRATEGIC DEVELOPMENTS
9.1.1 MERGERS & ACQUISITIONS
9.1.2 PARTNERSHIPS & AGREEMENTS
9.2 COMPANY PROFILES
9.2.1 ABBOTT LABORATORIES
9.2.2 ACELLA PHARMACEUTICALS LLC
9.2.3 ASTRAZENECA PLC
9.2.4 CIPLA LIMITED
9.2.5 DABUR INDIA LTD
9.2.6 GLAXOSMITHKLINE PLC
9.2.7 GLENMARK PHARMACEUTICAL LIMITED
9.2.8 JOHNSON & JOHNSON
9.2.9 MERCK KGAA
9.2.10 NOVARTIS INTERNATIONAL AG
9.2.11 PFIZER INC
9.2.12 PROCTOR & GAMBLE CO (P&G)
9.2.13 RECKITT BENCKISER GROUP PLC
9.2.14 SANOFI SA
9.2.15 THE HIMALAYA DRUG COMPANY